Monitor Guardant Health's relative TSR performance against the S&P 500 over the next 3-5 years to assess potential dilution from PSU vesting. No immediate trading catalyst from this filing.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+5- T+0 · Nov 3 $175.00entry
- T+1 · 13d ago −3.67%α −5.32% · $168.58
- T+5 · 7d ago −11.23%α −10.64% · $155.35
- T+9 · todayOpen
- T+20 · in 15d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Guardant Health granted 465,413 performance-based restricted stock units (PSUs) at target to each of its co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, under the 2018 Incentive Award Plan. The PSUs are 100% performance-based, tied to the company's total shareholder return relative to the S&P 500 over three-year and five-year periods, with post-vest holding requirements. This is a routine compensatory arrangement for continuing executives with no departure or appointment.
Key Facts
- Each co-CEO received 465,413 target PSUs (116,353 3-year PSUs and 349,060 5-year PSUs).
- PSUs vest based on relative TSR vs. S&P 500 over 3-year (June 1, 2026 - May 31, 2029) and 5-year (June 1, 2026 - May 31, 2031) performance periods.
- Earned PSUs range from 0% to 250% of target based on relative TSR percentile, capped at 100% if absolute TSR is negative.
- Post-vest transfer restrictions apply: 3-year PSUs locked for one year ending May 31, 2030; 50% of net 5-year PSUs locked for six months ending November 30, 2031.
- The company reported a 275% total shareholder return over the last three fiscal years.
Financial Impact
No immediate financial impact; potential dilution of up to 930,826 shares (465,413 per co-CEO) at maximum 250% payout, but vesting is contingent on performance over 3-5 years.
Risk Factors
- Potential dilution if PSUs vest at maximum 250% of target, adding up to 930,826 shares.
- PSU performance conditions are tied to relative TSR, which may be affected by market conditions and sector performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-444416 |
| Document: d457424d8k.htm | 0001193125-26-444416 |
| Document: 0001193125-26-444416-index-headers.html | 0001193125-26-444416 |
| Document: 0001193125-26-444416-index.html | 0001193125-26-444416 |
| Document: 0001193125-26-444416.txt | 0001193125-26-444416 |
Track record
38 reports on GH
3 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.49% at T+60 after the May 27, 2026 report. 4 of 7 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $145.04 Now $144.03 −0.70% settles Dec 16
- Nov 12, 20264d ago 3 Neutral 1/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $151.70 Now $144.03 −5.06% settles Dec 14
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $150.87 Now $144.03 −4.53% settles Dec 7
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $153.43 Now $144.03 −6.13% settles Dec 4
- Nov 3, 202613d ago 8-K Neutral 2/10 Entry $168.58 Now $144.03 −14.56% settles Dec 3
- Nov 3, 202613d ago 8-K Neutral 2/10 Viewing Entry $175.00 Now $144.03 −17.70% settles Dec 2
- Oct 21, 202626d ago Institutional Cluster Neutral 3/10 Entry $162.94 Now $144.03 −11.61% settles Nov 19
- Oct 14, 20264w ago 144 Neutral 2/10 Entry $165.88 to $154.86 Now $144.03 −13.17% ▼ −6.64% −4.74% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 5/10 Entry $179.38 to $158.60 Now $144.03 +19.71% ▲ +11.58% +11.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers